ArticleArchives of medical sciences. Atherosclerotic diseases2024
ST-segment elevation myocardial infarction for pharmacoinvasive strategy or primary percutaneous coronary intervention in Gaza (STEPP 2- PCI) trial.
Article in Archives of medical sciences. Atherosclerotic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- First medical contact-to-balloon time and in-hospital outcomes of primary percutaneous coronary intervention for ST-elevation myocardial infarction in Jenin, Palestine: a retrospective cohort study (2023-2024).BMC cardiovascular disorders · 2026Article
- The Irreversible March of Time: Ischemic Delay and Impact on Outcomes in ST-Segment Elevation Myocardial Infarction.Journal of cardiovascular development and disease · 2025Review
- ST-segment elevation myocardial infarction for pharmacoinvasive strategy or primary percutaneous coronary intervention in Gaza (STEPP 2- PCI) trial.Archives of medical sciences. Atherosclerotic diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary percutaneous coronary intervention (P-PCI) is still preferred as the optimal reperfusion therapy among patients with ST-segment elevation myocardial infarction (STEMI). However, in non-PCI capable hospitals, pharmacoinvasive treatment (Ph-PCI) can be performed as alternative therapy to P-PCI. This study compares the efficacy between a Ph-PCI and P-PCI strategies among patients with STEMI. Material and methods: We conducted a retrospective analysis of patients with STEMI presenting within 12 h of symptoms onset assigned to two groups: Group 1 ( Results: In total, 308 patients presented with acute STEMI (≤ 12 h from symptom onset to first medical contact), mean age 58.05 ±11.3 years; 257 (83.5%) patients were male. The primary endpoint in P-PCI was observed in 16.2% and in Ph-PCI 8.4%; Conclusions: Ph-PCI was associated with decreased composite endpoints of mortality and heart failure outcomes during 30 days after STEMI and improved ST-segment resolution within 1 h after percutaneous coronary intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.